Virus cocktail inhaled to fight Drug-Resistant lung infection

NCT ID NCT05616221

Completed Disease control Sponsor: Armata Pharmaceuticals, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested an inhaled mixture of bacteria-killing viruses (phages) in 48 adults with bronchiectasis and chronic Pseudomonas lung infections. Participants received either the phage therapy or a placebo by inhalation. The goal was to see if the phages could safely reduce the amount of bacteria in the lungs.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: AP-PA02 (a mixture of viruses that kill bacteria, called bacteriophages, inhaled as a mist)
What this could lead to: If it works, this could offer a new way to control stubborn lung infections in people with bronchiectasis, reducing the need for antibiotics.
What could go wrong: This is a small, early-phase trial with only 48 participants. The treatment may not reduce bacteria enough, and side effects from inhaling phages are still being studied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

bronchiectasis pneumonia Pseudomonas aeruginosa infectious disease Pseudomonas infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LUNG INFECTION NON-CYSTIC FIBROSIS BRONCHIECTASIS PSEUDOMONAS AERUGINOSA

Contacts and locations

Locations

Georgetown University Hospital / Pulmonary Critical Care and Sleep Medicine

Washington D.C., District of Columbia, 20007, United States
Johns Hopkins University School of Medicine

Baltimore, Maryland, 21224, United States
Mayo Clinic

Rochester, Minnesota, 55905, United States
Mayo Clinic/Pulmonary, Critical Care, and Sleep Medicine

Jacksonville, Florida, 32224, United States
Medical University of South Carolina

Charleston, South Carolina, 29425, United States
New York Medical College

Hawthorne, New York, 10595, United States
Oregon Health & Science University

Portland, Oregon, 97239, United States
Rutgers Robert Wood Johnson Medical School

New Brunswick, New Jersey, 08901, United States
Southern California Institute for Respiratory Diseases Cedars-Sinai West Tower

Los Angeles, California, 90048, United States
Southwest General Healthcare Center

Fort Myers, Florida, 33907, United States
St. Lukes Hospital

Boise, Idaho, 83702, United States
TecTum Medical Research, Inc.

Hollywood, Florida, 33024, United States
The University of Kansas Medical Center / Dept of Medicine

Kansas City, Kansas, 66160, United States
UCONN Health

Farmington, Connecticut, 06030, United States
University Hospitals of Cleveland Medical Center

Cleveland, Ohio, 44106, United States
University of Cincinnati - College of Medicine

Cincinnati, Ohio, 45267, United States
University of Miami

Miami, Florida, 33146, United States
University of Pennslyvania

Philadelphia, Pennsylvania, 19104, United States
University of Texas Health Science Center at Tyler

Tyler, Texas, 75708, United States
University of Washington Medical Center

Seattle, Washington, 98195, United States
Vanderbilt University Medical Center

Nashville, Tennessee, 37203, United States
Velocity Clinical Research

Mobile, Alabama, 36608, United States
Virginia Commonwealth University (VCU)

Richmond, Virginia, 23298, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.